Selective reverse transcriptase inhibitor. Exhibits 100-fold selectivity for HIV reverse transcriptase over DNA polymerase α
. Suppresses HIV-1 replication and enhances cell viability in HIV-1 infected T cells. Attenuates growth of multiple myeloma (MM) cells in vitro
and reduces growth of MM tumor xenografts in mice. Orally bioavailable and brain penetrant. Antiretroviral agent. Also decreases CRISPR-mediated homology directed repair (HDR) efficiency.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Viiv.
Small Molecules Enhance CRISPR Genome Editing in Pluripotent Stem Cells.
Yu et al.
Cell Stem Cell, 2015;16:142
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
Mitsuya et al.
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
Furman et al.
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.
Antiviral Res., 2010;85:1
Azidothymidine is effective against human multiple myeloma: a new use for an old drug?
Pereira et al.
Anticancer Agents Med.Chem., 2013;13:186